Oxurion NV will file for bankruptcy following KALAHARI data release

News
Article

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint

Documents indicate a corporation filing for bankruptcy. Image credit: ©Minerva Studio – stock.adobe.com

The KALAHARI trial was the final ongoing trial sponsored by Oxurion. Image credit: ©Minerva Studio – stock.adobe.com

On Monday, Oxurion NV announced it would file for bankruptcy following the release of topline data from its KALAHARI Phase IIb clinical trial. The company, headquartered in Leuven, Belgium, did not demonstrate that its novel PKal Inhibitor, THR-149, improved vision as much as aflibercept at month 3, its primary endpoint.1 THR-149 was under development for treatment of diabetic macular oedema (DME). The KALAHARI trial was the final ongoing trial sponsored by Oxurion.

According to a news release from Oxurion, the mean change in best corrected visual acuity (BCVA) from baseline at the primary endpooint was -0.2 letters for the THR-149 arm and +3.5 letters for the aflibercept arm.1 Oxurion finalised enrollment in June with 112 patients, after initial plans to enroll 108 patients.2 The Phase II KALAHARI trial was a two-part, randomised, prospective, multi-centre trial assessing multiple (3) injections of THR-149 in DME patients. Part B was double-masked and actively controlled.

In a statement, Tom Graney, CEO of Oxurion, expressed gratitude for the diligent work contributed by the team members executing the trial. “We are deeply disappointed that the topline data from the KALAHARI trial did not show improvement in vision from THR-149. While we had hoped for a different result for patients, we greatly appreciate the engagement of both the patients and the clinical investigators for their participation in Phase 2 KALAHARI trial,” he said.1 “While the outcome is not what we had hoped for patients and the company, the trial provides important learnings for the field. I want to encourage the community to continue to invest in finding better treatments options for this large, underserved patient population.”

High-level data from KALAHARI Phase IIa was presented in October 2021. In December 2022, an Independent Data Monitoring Committee recommended the KALAHARI trial continue based on the outcome of a pre-specified futility analysis that included interim efficacy and safety data.

References

  1. Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema. News release. Oxurion NV. Published 20 November, 2023. https://www.globenewswire.com/news-release/2023/11/20/2782903/0/en/Oxurion-Discloses-Topline-Data-from-KALAHARI-Phase-2-Part-B-Trial-of-Novel-PKal-Inhibitor-THR-149-in-Diabetic-Macular-Edema.html
  2. Oxurion finalizes enrollment in KALAHARI phase 2, part B trial. Ophthalmology Times Europe. Published 12 June, 2023. Accessed 20 November, 2023. https://europe.ophthalmologytimes.com/view/oxurion-belgium-kalahari-trial-diabetic-macular-edema

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Related Content
© 2025 MJH Life Sciences

All rights reserved.